Rani Therapeutics Holdings, Inc. Class A Common Stock
RANIRani Therapeutics Holdings, Inc. Class A (RANI) is a biopharmaceutical company focused on developing oral biologic delivery platforms. Their flagship technology involves using an ingestible, self-orienting robotic pill to deliver biologic drugs orally, aiming to replace injections for various conditions. The company is committed to advancing innovative drug delivery solutions to improve patient experiences and treatment outcomes.
Company News
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These confer...
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’...
U.S. stock futures were higher this morning, with the Dow futures gaining over 50 points on Thursday. Shares of Equifax Inc. (NYSE: EFX) fell sharply in today’s pre-market trading after the company reported worse-than-expected first-quarter sales results and issued adjusted guidance below estimates. Equifax posted quarterly sales of $1.389 bil...
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' expectations. Core income per share reached $4.69 from $4.11 a year ago, missing the $4.90 consensus forecast. Net income per share rose to $4.80 ...
